Gossamer Bio, Inc. Common Stock

Day range

$9.00 – $9.64

Open

$9.61

Prev close

$9.61

Volume

99.53K

Market cap

$58.75M

Shares out

6.12M

P/E

—

P/S

1.10

P/B

-0.63

P/FCF

—

ROE

133.2%

ROA

-162.9%

Debt/Equity

-0.38

Div yield

0.00%

As of Oct 23, 2026

• Stock splitSep 28, 2026

  As previously disclosed, on September 10, 2026, the Company effected a 1-for-80 reverse stock split of its common stock, and the Company's common stock began trading on a split-adjusted basis on the Nasdaq Global Select Market on September 11, 2026.

• Private placementSep 16, 2026

  As previously announced, on August 24, 2026, the Company held the initial closing of a private placement transaction (the "2026 PIPE"), pursuant to which Mr. Ciongoli was a purchaser under that certain Securities Purchase Agreement, dated August 20, 2026, by and among the Company and the purchasers named therein.

• Stock splitSep 11, 2026

  On September 10, 2026, the Company filed ... a Certificate of Amendment ... to effect the 1-for-80 reverse stock split of the Common Stock ... The Charter Amendment became effective at 11:59 p.m. Eastern Time on September 10, 2026.

• Charter amendmentSep 9, 2026

  The stockholders of Gossamer Bio, Inc. approved thirty alternate amendments to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split ... and a proportionate reduction in the number of authorized shares of Common Stock.

• Bylaw amendmentSep 3, 2026

  On and effective as of September 3, 2026, the Board of Directors (the "Board") of Gossamer Bio, Inc. (the "Company") approved the amendment and restatement of the amended and restated bylaws of the Company... to reduce the requisite quorum at all meetings of stockholders for the transaction of business from the holders of a majority to the holders of one third (1/3) in voting power of the Company's capital stock issued and outstanding and entitled to vote.

Days to cover

3.5

Short interest

1.24M

Avg volume

353.41K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
  positiveGlobeNewswire Inc.· Sep 16, 2026
• GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
  negativeGlobeNewswire Inc.· May 31, 2026
• GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
  negativeGlobeNewswire Inc.· May 31, 2026
• GOSS DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action – GOSS
  negativeGlobeNewswire Inc.· May 30, 2026
• Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS
  negativeGlobeNewswire Inc.· May 29, 2026